HS 10234

Drug Profile

HS 10234

Alternative Names: HS10234

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Jilin University; Shanghai Hansen Biomedical Technology
  • Class
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 11 May 2017 Hansoh Pharma files for patent protection for HS 10234 (WO2016011932 A1)
  • 16 Dec 2016 Phase-I clinical trials in Hepatitis B in China (PO) (ChiCTR-IIR-17011107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top